151038-95-8

Basic information

• Product Name: 2-[6-(2,5-Dioxo-1H-pyrrol-1-yl)-1-oxohexyl]hydrazinecarboxylic acid, 1,1-dimethylethyl ester
• CAS NO: 151038-95-8
• Molecular Weight: 325.365
• Mol File: 151038-95-8.mol
• Article Data: 4

Chemical Properties

• Density: 1.202±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-[6-(2,5-Dioxo-1H-pyrrol-1-yl)-1-oxohexyl]hydrazinecarboxylic acid, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[6-(2,5-Dioxo-1H-pyrrol-1-yl)-1-oxohexyl]hydrazinecarboxylic acid, 1,1-dimethylethyl ester(151038-95-8)
• EPA Substance Registry System: 2-[6-(2,5-Dioxo-1H-pyrrol-1-yl)-1-oxohexyl]hydrazinecarboxylic acid, 1,1-dimethylethyl ester(151038-95-8)

Safety Data

• Hazardous Substances Data: 151038-95-8(Hazardous Substances Data)

Usage

Uses

6-Maleimidocaproic tert-Butylcarbazate is used in the preparation of Doxorubicin (6-maleimidocaproyl)hydrazone with antigen-specific cytotoxicity.

Upstream product

• 55750-53-3 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid 
• 543-27-1 isobutyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 60-32-2 6-aminohexanoic acid 
• 57079-14-8 6-(3-carboxyacryloylamino)caproic acid 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 151038-94-7 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide trifluoroacetate 

Relevant articles and documents

Elastic targeting polypeptide-based medicine-carrying nanoparticle as well as preparation method and application thereof

The invention discloses an elastic targeting polypeptide-based medicine-carrying nanoparticle. The nanoparticle is prepared from an elastic targeting polypeptide and a modified medicine, wherein the modified medicine is a modified paclitaxel PTX-LEV-MECH or modified salinomycin Sail-ABA-MPBH. The elastic targeting polypeptide-based medicine-carrying nanoparticle provided by the invention is 100nmor below in particle size, so that the dispersion degree is low, the medicine carrying rate is high, and the nanoparticle can be combined with in-vivo albumin for transferring and carrying medicine, and also can be combined with acidic rich cysteine specifically secreted by tumor cells, the drug is concentrated in the acidic environment, the breast cancer in-situ cancer is targeted for killing, and the toxic and side effects of the drug on the whole body are reduced; and the efficacy of treating breast cancer is increased and improved by utilizing the synergistic effect of two nanoparticles, the occurrence of the metastasis of the breast cancer cells through a lymphatic system and a blood system is reduced, and the occurrence of serious complications such as medical-source lymphatic edemacaused by a lymph node sweeping surgery is reduced.

Synthesis of heterobifunctional crosslinking reagents: ω-(N-Maleimido)-alkanoic acid hydrazides

ω-(N-Maleimido)alkanoic acid hydrazides (6a-c) with C11, C7 and C5 alkyl arms have been synthesized by novel method. The method involves the reaction between maleic anhydride and ω-aminoalkanoic acids (2) to get maleamic acids (3) which are in turn cyclized to ω-(N-maleimido)alkanoic acids (4) using fused sodium acetate and acetic anhydride. These maleimidoalkanoic acids are activated and then converted in situ into their N-2-t-butyloxycarbonyl hydrazides (5) from which the t-butyl-based protecting group is cleaved without damage to the maleimide molety to obtain the title compounds.